ML-319

N/A

Report date: 2024/12/04 11:16:03
NME

Base Information

Drug NameML-319
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase BTK inhibitors
TargetsTyrosine-protein kinase BTK
Therapy Area/IndicationsLymphoma, Mantle-CellLymphoma, Non-HodgkinLeukemia, Lymphocytic, Chronic, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesJiangsu Maidu Pharmaceutical R & D Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesJiangsu Maidu Pharmaceutical R & D Co Ltd
Inactive CompaniesN/A
Active IndicationsLymphoma, Mantle-CellLymphoma, Non-HodgkinLeukemia, Lymphocytic, Chronic, B-Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A